Cencora Inc. has announced the amendment and restatement of its existing Revolving Credit Facility. The updated agreement, effective as of June 4, 2025, involves Cencora and its subsidiaries, BP Pharmaceuticals Laboratories Unlimited Company and Innomar Strategies Inc., in collaboration with several lenders, including JPMorgan Chase Bank, N.A. as the administrative agent. Key changes to the facility include an increase in the total commitment to $4.5 billion and an extension of the maturity date to June 4, 2030. Additionally, certain covenants and provisions have been revised. The involved lenders and their affiliates have a history of providing various financial services to Cencora and may continue to do so in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。